CompletedPhase 1NCT00609999

Ph I Dasatinib + Erlotinib in Recurrent MG

Studying Gliosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Duke University
Principal Investigator
Annick Desjardins, MD, FRCPC, M.D
Duke Health
Intervention
Erlotinib and Dasatinib(drug)
Enrollment
47 enrolled
Eligibility
18 years · All sexes
Timeline
20082010

Study locations (1)

Collaborators

Bristol-Myers Squibb · Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00609999 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma

← Back to all trials